The vaccines will be developed using Touchlight’s doggybone DNA technology, which speeds up the manufacturing process.
Touchlight’s enzymatic doggybone DNA used in manufacture of Versameb’s VMB-100
Albany, NY and Hampton, UK – July 24, 2023 – Curia, a leading contract research, development and manufacturing organization, and Touchlight, a company pioneering enzymatic DNA production, today announced an agreement which will provide Curia and its clients a streamlined means of access to Touchlight’s doggybone DNA (dbDNA). The arrangement expands Curia’s mRNA manufacturing offerings with an additional differentiated source of DNA raw material that is immediately available to be accessed by Curia customers. Under the arrangement, Touchlight will directly manufacture dbDNA on behalf of Curia’s customers.
Touchlight launches its new customer offering of Discovery grade doggybone DNA (dbDNA)
HAMPTON, England--(BUSINESS WIRE)--Touchlight, a company pioneering enzymatic DNA production, a critical material in many new genetic medicine treatments, has completed the redevelopment and expansion of its UK manufacturing facility, housed in a repurposed Victorian waterworks on the banks of the River Thames.
Touchlight and 20Med partner on vaccine platform
Touchlight secures government grant to support its £14m investment in scale-up DNA manufacturing
Touchlight Genetics Ltd., a Contract Development and Management Organization (CDMO) pioneering enzymatic DNA production to enable genetic medicines, announced the first FDA clearance of an Investigational New Drug (IND) application using doggybone DNA (dbDNA).
FDA Accepts Drug Master File, Signifying a New Milestone for Touchlight’s Enzymatic doggybone DNA Technology
Touchlight and Odimma Therapeutics have entered an agreement for the development and supply of clinical material for usage in the latter’s neoantigen programme for cancer.